EP4419094A4 - Compositions and methods for treating hyperproliferative, inflammatory and immunological diseases and infections - Google Patents

Compositions and methods for treating hyperproliferative, inflammatory and immunological diseases and infections

Info

Publication number
EP4419094A4
EP4419094A4 EP22884534.3A EP22884534A EP4419094A4 EP 4419094 A4 EP4419094 A4 EP 4419094A4 EP 22884534 A EP22884534 A EP 22884534A EP 4419094 A4 EP4419094 A4 EP 4419094A4
Authority
EP
European Patent Office
Prior art keywords
infections
inflammatory
compositions
methods
immunological diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22884534.3A
Other languages
German (de)
French (fr)
Other versions
EP4419094A1 (en
Inventor
Jeffrey A Bacha
Dennis Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edison Oncology
Original Assignee
Edison Oncology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Oncology filed Critical Edison Oncology
Publication of EP4419094A1 publication Critical patent/EP4419094A1/en
Publication of EP4419094A4 publication Critical patent/EP4419094A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22884534.3A 2021-10-21 2022-10-21 Compositions and methods for treating hyperproliferative, inflammatory and immunological diseases and infections Pending EP4419094A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163270382P 2021-10-21 2021-10-21
PCT/US2022/047447 WO2023069727A1 (en) 2021-10-21 2022-10-21 Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections

Publications (2)

Publication Number Publication Date
EP4419094A1 EP4419094A1 (en) 2024-08-28
EP4419094A4 true EP4419094A4 (en) 2025-10-15

Family

ID=86059594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22884534.3A Pending EP4419094A4 (en) 2021-10-21 2022-10-21 Compositions and methods for treating hyperproliferative, inflammatory and immunological diseases and infections

Country Status (5)

Country Link
EP (1) EP4419094A4 (en)
AU (1) AU2022370861A1 (en)
CA (1) CA3235940A1 (en)
IL (1) IL312343A (en)
WO (1) WO2023069727A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116898830A (en) * 2023-08-14 2023-10-20 上海交通大学医学院附属第九人民医院 Use of irismol in the preparation of medicines that promote skin wound healing
WO2025076109A1 (en) * 2023-10-04 2025-04-10 Edison Oncology Holding Corp. Use of elesclomol to treat clear-cell ovarian cancers with mutations in arid1a

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128580A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815945B2 (en) * 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
JP6821560B2 (en) * 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． Cancer treatment with immunostimulants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128580A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS ET AL: "Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", FDA, 1 July 2005 (2005-07-01), pages 1 - 30, XP093183231, Retrieved from the Internet <URL:https://www.fda.gov/media/72309/download> *
BUCCARELLI MARIACHIARA ET AL: "Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 40, no. 1, 12 July 2021 (2021-07-12), London UK, XP093307868, ISSN: 1756-9966, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s13046-021-02031-4/fulltext.html> DOI: 10.1186/s13046-021-02031-4 *
FARIA ANA R. ET AL: "Cubosome nanoparticles for enhanced delivery of mitochondria anticancer drug elesclomol and therapeutic monitoring via sub-cellular NAD(P)H multi-photon fluorescence lifetime imaging", NANO RESEARCH, vol. 12, no. 5, 1 May 2019 (2019-05-01), CN, pages 991 - 998, XP093109028, ISSN: 1998-0124, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s12274-018-2231-5.pdf> DOI: 10.1007/s12274-018-2231-5 *
J. KLUZA ET AL: "Inactivation of the HIF-1 /PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants", CANCER RESEARCH, vol. 72, no. 19, 1 October 2012 (2012-10-01), pages 5035 - 5047, XP055058978, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-0979 *
KWAN SUET-YAN ET AL: "Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells", ONCOTARGET, vol. 7, no. 35, 29 July 2016 (2016-07-29), United States, pages 56933 - 56943, XP093307703, ISSN: 1949-2553, DOI: 10.18632/oncotarget.10921 *
See also references of WO2023069727A1 *

Also Published As

Publication number Publication date
CA3235940A1 (en) 2023-04-27
AU2022370861A1 (en) 2024-06-06
WO2023069727A1 (en) 2023-04-27
EP4419094A1 (en) 2024-08-28
IL312343A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
EP4034138A4 (en) COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER
EP4132507A4 (en) METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS
EP4157448A4 (en) METHODS AND COMPOSITIONS FOR TREATING RNA VIRUS INFECTIONS
EP4415755A4 (en) ACE2-TARGETED COMPOSITIONS AND METHODS FOR THE TREATMENT OF COVID-19
EP4203990A4 (en) Methods and compositions for the treatment of glioblastoma
EP4096439A4 (en) COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES
EP3986439A4 (en) COMPOSITIONS AND METHODS FOR TREATING BRAIN DISEASES
EP4189063A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL TRACT INFECTIONS
EP4171606A4 (en) COMPOSITIONS AND METHODS FOR TREATING COVID-19
EP4419094A4 (en) Compositions and methods for treating hyperproliferative, inflammatory and immunological diseases and infections
EP4405048A4 (en) METHODS FOR THE TREATMENT OF INFLAMMATORY EYE DISEASES
EP4097236A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES
EP4337174A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
EP4340860A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPATHY
EP3917923A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF MYOPIA
EP4225371A4 (en) METHODS FOR TREATING OX40-RELATED DISEASES
EP4096653A4 (en) COMPOSITIONS FOR TREATING ANGIOLIPOMA
EP4034109A4 (en) METHOD AND COMPOSITION FOR TREATING DISEASES
EP4003485A4 (en) INTRAVAGINAL DEVICES, COMPOSITIONS AND METHODS FOR TREATING ATROPHIC VAGINITIS
EP4398921A4 (en) Compositions and methods for treating ovarian aging, ovarian diseases and conditions, and symptoms thereof
EP4308116A4 (en) Methods and compositions for treating eye diseases
EP4181942A4 (en) METHODS FOR TREATING NEUTROPHIL-DRIVEN INFLAMMATORY DISEASES
EP4436576A4 (en) METHODS FOR TREATMENT OF SARS-COV-2 INFECTIONS
EP3823626A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM
EP4370654A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES II

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250917

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/18 20060101AFI20250911BHEP

Ipc: A61P 35/00 20060101ALI20250911BHEP

Ipc: C12Q 1/68 20180101ALI20250911BHEP

Ipc: G01N 33/50 20060101ALI20250911BHEP

Ipc: A61K 45/06 20060101ALI20250911BHEP